Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | F2R | P25116 | 3/20 | 0.39 |
| ▸ | FCER2 | P06734 | 4/20 | 0.39 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12340166 | 0.92 | KLKB1 (0.41) | F7KLKB1MMP8LCKF2R | |
| SCHEMBL12340175 | 0.88 | KLKB1 (0.49) | F7KLKB1F2RFCER2MMP1 | |
| SCHEMBL12340165 | 0.76 | F2R (0.49) | KLKB1LCKF2R | |
| SCHEMBL13945252 | 0.74 | F2R (0.52) | F2R | |
| SCHEMBL13945250 | 0.72 | F2R (0.44) | KLKB1LCKF2R | |
| SCHEMBL4202829 | 0.66 | TP53 (0.52) | — | |
| SCHEMBL14485541 | 0.65 | KLKB1 (0.68) | KLKB1MMP8 | |
| SCHEMBL18787564 | 0.64 | SSTR3 (0.54) | FCER2 | |
| SCHEMBL14115004 | 0.64 | NPY1R (0.53) | KLKB1FCER2MMP1 | |
| SCHEMBL7947333 | 0.64 | TACR2 (0.63) | F7KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012006-A1 | Par-2 Antagonists | F2RL1, F2R, F2RL3 | F7 1492/4885KLKB1 503/4885MMP8 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.